Solid tumours, haemoblastoses & lymphomas eg, acute myeloid or lymphatic leucaemia, Hodgkin's & non-Hodgkin's lymphoma; carcinomas of the mamma, urinary bladder, bronchial tubes, cervix, ovary, stomach, thyroid, testicle; neuroblastoma, soft tissue sarcoma, osteosarcoma, (Ewing sarcoma), Wilms' tumour, tumours of the head & neck, multiple myelomas. Intravesical administration in case of superficial non-invasive bladder carcinomas after transurethral resection (TUR) & for recidive prophylaxis.
Dosage/Direction for Use
Adult Monotherapy: 60-75 mg/m2 (1.2-2.4 mg/kg) IV in a 21-day interval or 20-25 mg/m2 (0.4-0.8 mg/kg) IV over 3 successive days or 20 mg/m2 wkly. Elderly >70 yr Cumulative dose should not exceed 450 mg/m2.
Contraindications
Hypersensitivity. Severe bone marrow suppression, cardiopathologic anamnesis, severe liver & renal impairment, uncontrolled infections, increased haemorrhagic tendency. Intravesical administration: cystitis, invasive tumours that penetrate the vesical wall. Marked myelosuppression, buccal ulceration or burning sensation. Pregnancy & lactation.
Special Precautions
Monitor haematologic & cardiologic parameters, control liver & renal functions, blood urea level & systemic infections. Previous cardiac diseases or therapy w/ cardiotoxic substances (eg, anthracyclines). Simultaneous or previous radiotherapy of the mediastinal-pericardial field, disease-dependent clinical conditions (eg, anaemia, leucaemic pericarditis &/or myocarditis).
Sign Out
